Metastatic nonseminomatous germ cell tumors of the testis
Open Access
- 15 March 2002
- Vol. 94 (6), 1668-1676
- https://doi.org/10.1002/cncr.10440
Abstract
BACKGROUND A mass may persist in the para‐aortic region after patients undergo chemotherapy for metastatic, nonseminomatous germ cell tumor of the testis (NSGCT). Retroperitoneal lymphadenectomy removes the mass, which may contain residual active malignancy, and allows histologic assessment of the effectiveness of the chemotherapy. Whereas some have favored early, elective removal of such masses, others have chosen to observe them, reserving salvage surgery for patients who experience disease recurrence. A retrospective analysis was undertaken to define the outcome in these two groups of patients. METHODS After receiving chemotherapy for metastatic NSGCT, 442 men underwent lymphadenectomy for residual masses (measuring ≥ 1 cm in greatest dimension) between 1976 and 1999, inclusive. Three hundred thirty men underwent elective surgery within 3 months of the completion of chemotherapy, and 112 men underwent salvage surgery after receiving reinduction chemotherapy for tumor recurrence. RESULTS The residual mass was removed completely in 87% and 72% of patients in the elective and salvage lymphadenectomy groups, respectively; was removed with difficulty and possibly incompletely in 9% and 21% of patients, respectively; and was definitely removed incompletely in 4% and 7% of patients, respectively. The operative mortality rate was 0.9% in the elective surgery group and 1.8% in the salvage surgery group. There was malignant teratoma, undifferentiated in 8.5% of patients in the elective surgery group and in 49% of patients in the salvage surgery group (P < 0.001). Differentiated teratoma and necrosis/fibrosis were present in 66.0% and 25.4% of patients in the elective surgery group, respectively, and in 38.4% and 12.5% of patients in the salvage surgery group, respectively. The authors were unable to produce a clinically useful model to predict the presence of necrosis/fibrosis only in either group. The 5‐year recurrence free and overall survival rates were 83% and 89%, respectively, in the elective surgery group and 62% and 56%, respectively, in the salvage surgery group. For the salvage surgery group, the completeness of surgical excision and the presence of undifferentiated teratoma were of overriding importance for overall survival. A variety of other patient‐related, tumor‐related, and surgery‐related factors also were significant in the final model for the elective surgery group. CONCLUSIONS The current results demonstrate the low level of morbidity that can be obtained, even in the salvage surgery group, and the importance of complete surgical resection in this setting. Because it is not possible to predict with sufficient accuracy which patients will have favorable pathology (necrosis/fibrosis), the authors continue to recommend elective surgery for all suitable men with residual masses after they receive first‐line chemotherapy. Cancer 2002;94:1668–76. © 2002 American Cancer Society. DOI 10.1002/cncr.10440This publication has 49 references indexed in Scilit:
- Retroperitoneal lymphadenectomy for post‐chemotherapy residual masses: is a modified dissection and resection of residual masses sufficient?British Journal of Urology, 1998
- Decision making in abdominal surgery following chemotherapy for testicular cancerEuropean Journal Of Cancer, 1995
- Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: Long-term follow-upEuropean Journal of Cancer and Clinical Oncology, 1991
- Excision of residual masses after platinum based chemotherapy for non-seminomatous germ cell tumoursEuropean Journal of Cancer and Clinical Oncology, 1989
- Clinical and radiological correlation of retroperitoneal metastasis from nonseminomatous testicular cancer treated with chemotherapyEuropean Journal of Cancer and Clinical Oncology, 1989
- Significance of Salvage Lymphadenectomy in the Therapeutical Concept of Advanced Nonseminomatous Germ Cell TumorsUrologia Internationalis, 1989
- Testicular relapse after chemotherapy for malignant teratoma.BMJ, 1987
- The Role of Surgery in the Combined Management of Metastases from Malignant Teratomas of TestisBritish Journal of Urology, 1987
- The Detection and Localisation of Abdominal Lymph Node Metastases from Testicular TeratomasBritish Journal of Urology, 1977
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958